PBAC to review opioid prescribing

March date set for new report on 'all strengths and all brands'

The prescribing of every single brand and strength of opioid funded by taxpayers will be reviewed by a PBAC expert committee over the next two months.


The Drug Utilisation Subcommittee (DUSC), which conducts post-marketing reviews for the PBAC, has been commisioned to write up the wide-ranging report.

While terms of reference have yet to be formalised, the aim is to track the use of all PBS-listed opioid analgesics by analysing data that includes patient age groups and the number of individual patients being dispensed multiple scripts long-term.